Molecure S.A. (WSE:MOC)
Poland · Delayed Price · Currency is PLN 5.95
+0.06 (1.02%)
Jul 24, 2026, 5:00 PM CET
Molecure Earnings Call Transcripts
Fiscal Year 2024
-
Two main clinical programs advanced, with QATD-01 (sarcoidosis) and QATD-02 (solid tumors) progressing in enrollment and dose escalation, respectively. Financials show reduced costs and stable capital, with ongoing efforts to secure partnerships and grants to fund future development.